Review
doi: 10.3949/ccjm.84a.16091.
Use and misuse of opioid agonists in opioid addiction
Affiliations
- PMID: 28530896
- DOI: 10.3949/ccjm.84a.16091
Item in Clipboard
Review
Use and misuse of opioid agonists in opioid addiction
Cleve Clin J Med.
2017 May.
Free article
Abstract
Although methadone (an opioid agonist) and buprenorphine (a partial opioid agonist) have evidence to support their use in treating opioid use disorder, they remain misunderstood and underutilized. In this article, we outline the risks and benefits of using these drugs as maintenance therapy in opioid-dependent patients.
Copyright © 2017 Cleveland Clinic.
Similar articles
-
Neonatal outcomes following in utero exposure to methadone or buprenorphine: a National Cohort Study of opioid-agonist treatment of Pregnant Women in Norway from 1996 to 2009.Drug Alcohol Depend. 2013 Jan 1;127(1-3):200-6. doi: 10.1016/j.drugalcdep.2012.07.001. Epub 2012 Jul 25. Drug Alcohol Depend. 2013. PMID: 22841456
-
Maintenance medication for opiate addiction: the foundation of recovery.J Addict Dis. 2012;31(3):207-25. doi: 10.1080/10550887.2012.694598. J Addict Dis. 2012. PMID: 22873183 Free PMC article. Review.
-
Methadone and buprenorphine treatments in patients with schizophrenia.Schizophr Res. 2019 Jul;209:286-288. doi: 10.1016/j.schres.2019.05.013. Epub 2019 May 14. Schizophr Res. 2019. PMID: 31101511 No abstract available.
-
Expanding Treatment Opportunities for Hospitalized Patients with Opioid Use Disorders.J Hosp Med. 2018 Jan;13(1):62-64. doi: 10.12788/jhm.2861. Epub 2017 Oct 18. J Hosp Med. 2018. PMID: 29073311
-
Opioid agonist treatment for pharmaceutical opioid dependent people.Cochrane Database Syst Rev. 2016 May 9;(5):CD011117. doi: 10.1002/14651858.CD011117.pub2. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2022 Sep 5;9:CD011117. doi: 10.1002/14651858.CD011117.pub3. PMID: 27157143 Updated. Review.
Cited by
-
County-level factors associated with a mismatch between opioid overdose mortality and availability of opioid treatment facilities.PLoS One. 2024 Apr 5;19(4):e0301863. doi: 10.1371/journal.pone.0301863. eCollection 2024. PLoS One. 2024. PMID: 38578818 Free PMC article.
-
Glial Cells and Their Contribution to the Mechanisms of Action of Cannabidiol in Neuropsychiatric Disorders.Front Pharmacol. 2021 Feb 4;11:618065. doi: 10.3389/fphar.2020.618065. eCollection 2020. Front Pharmacol. 2021. PMID: 33613284 Free PMC article. Review.
-
Non-Opioid Treatments for Opioid Use Disorder: Rationales and Data to Date.Drugs. 2020 Oct;80(15):1509-1524. doi: 10.1007/s40265-020-01373-1. Drugs. 2020. PMID: 32776315 Free PMC article. Review.
-
Diverse TRPV1 responses to cannabinoids.Channels (Austin). 2019 Dec;13(1):172-191. doi: 10.1080/19336950.2019.1619436. Channels (Austin). 2019. PMID: 31096838 Free PMC article.
-
A Review of the Opioid Epidemic: What Do We Do About It?Pain Ther. 2018 Jun;7(1):23-36. doi: 10.1007/s40122-018-0096-7. Epub 2018 Apr 6. Pain Ther. 2018. PMID: 29623667 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
